HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $13 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Andrew Fein reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $13 price target.
HC Wainwright & Co. analyst Andrew Fein reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $13 price target.